ReviewFrontiers in oncology2022
Intracranial Metastatic Disease: Present Challenges, Future Opportunities.
Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 13 citations in OpenAlex.
- Exclusion of patients with brain metastases from early-phase systemic therapy trials: a cross-sectional analysis of eligibility criteria.Journal of neuro-oncology · 2026Article
- Machine learning identifies prognosticators of intracranial metastatic disease in patients with breast or lung cancer.Communications medicine · 2026Article
- Management of brain metastases in older adults with non-small cell lung cancer.Frontiers in oncology · 2026Review
- Brain metastases from ovarian cancer: neuroradiological profile and survival overview of neurosurgical cases.Journal of neuro-oncology · 2025Observational
- Hyperglycemia is associated with poor survival in patients with brain metastases treated with radiotherapy.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025Article
- Evaluating volumetric modulated arc therapy planning efficiency and dosimetric impact on non-contoured organ at risk in whole brain radiotherapy: a focus on oral cavity dose distribution.Revista da Associacao Medica Brasileira (1992) · 2025Article
- Brain metastasis burden and management in patients with small cell lung cancer in Canada: a retrospective, population-based cohort study.EClinicalMedicine · 2024Article
- Development of an optimized machine learning approach for assessing brain metastatic burden in preclinical models.bioRxiv : the preprint server for biology · 2024Article
- Long-term survival in patients with brain metastases-clinical characterization of a rare scenario.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024Article
- Article
- Personalized radiotherapy of brain metastases: survival prediction by means of dichotomized or differentiated blood test results?Frontiers in oncology · 2023Article
- Personalized treatment of brain metastases: Evolving survival prediction models may benefit from evaluation of serum tumor markers (narrative review).Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intracranial metastatic disease (IMD) is a prevalent complication of cancer that significantly limits patient survival and quality of life. Over the past half-century, our understanding of the epidemiology and pathogenesis of IMD has improved and enabled the development of surveillance and treatment algorithms based on prognostic factors and tumor biomolecular characteristics. In addition to advances in surgical resection and radiation therapy, the treatment of IMD has evolved to include monoclonal antibodies and small molecule antagonists of tumor-promoting proteins or endogenous immune checkpoint inhibitors. Moreover, improvements in the sensitivity and specificity of imaging as well as the development of new serological assays to detect brain metastases promise to revolutionize IMD diagnosis. In this review, we will explore current treatment principles in patients with IMD, including the emerging role of targeted and immunotherapy in select primary cancers, and discuss potential areas for further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.